FDA OKs 1st generic nasal spray of overdose reversal drug

National/World
Opioid Antidote Prescribing Narcan

FILE – In this Tuesday, July 3, 2018 file photo, a Narcan nasal device which delivers naloxone lies on a counter as a health educator gives instructions on how to administer it in the Brooklyn borough of New York. On Wednesday, Dec. 19, 2018, the U.S. government told doctors to consider prescribing the overdose antidote […]

U.S. regulators have approved the first generic nasal spray version of Narcan, a drug that reverses opioid overdoses.

The Food and Drug Administration on Friday OK’d naloxone spray from Israel’s Teva Pharmaceuticals.

Naloxone has been sold as a nasal spray in the U.S. since 2016 under the brand name Narcan. Pharmacists can dispense it without a prescription. It is also sold as a generic or brand-name drug in automatic injectors, prefilled syringes and vials.

A pack of two Narcan nasal sprays cost about $130 to $150 without insurance. Teva didn’t immediately provide the product’s price or when it will be available; its offices were closed Friday.

More than 47,600 Americans died of opioid overdoses in 2017, a toll that has been rising for two decades.

Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Don't Miss